Insider Shareholders with Direct Ownership of Syros Pharmaceuticals, Inc. (SYRS)
This section provides a comprehensive overview of the insiders with direct ownership of Syros Pharmaceuticals, Inc. (SYRS). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Syros Pharmaceuticals, Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
| 125,608 | 88,188 | 135,658 $328,292 | 9 |
Jun 05, 2024
Added 2.86%
|
|
|
Jason Haas
Chief Financial Officer |
136,208 | 11,656 | 124,552 $301,415 | 9 |
Sep 12, 2024
Added 26.69%
|
|
Conley Chee
President & CEO |
132,666 | 10,162 | 122,504 $296,459 | 8 |
Sep 11, 2024
Added 28.98%
|
|
Gerald E Quirk
Chief Legal & Compliance Offic |
55,000 | 17,043 | 46,657 $112,909 | 6 |
Sep 30, 2024
Reduced 6.23%
|
| 32,932 | 0 | 33,189 $80,317 | 5 |
Jun 05, 2024
Added 10.76%
|
|
|
Kristin Stephens
Chief Development Officer |
32,666 | 24,632 | 25,237 $61,073 | 7 |
Apr 01, 2024
Reduced 14.32%
|
| 16,000 | 0 | 16,000 $38,720 | 3 |
Jun 05, 2024
Added 20.0%
|
|
| 16,000 | 0 | 16,000 $38,720 | 3 |
Jun 05, 2024
Added 20.0%
|
|
| 16,000 | 0 | 16,000 $38,720 | 3 |
Jun 05, 2024
Added 20.0%
|
|
| 16,000 | 0 | 16,000 $38,720 | 3 |
Jun 05, 2024
Added 20.0%
|
|
| 12,000 | 0 | 12,000 $29,040 | 2 |
Jun 01, 2024
Added 25.0%
|
|
| 13,333 | 54,317 | 10,667 $25,814 | 11 |
Sep 16, 2024
Added 20.0%
|
|
| 9,333 | 0 | 9,333 $22,585 | 3 |
Sep 16, 2024
Added 22.23%
|
|
|
Eric R Olson
Chief Scientific Officer |
5,628 | 35,578 | 6,661 $16,119 | 8 |
Jul 17, 2023
Reduced 9.37%
|
|
Mark J Alles
Director |
2,666 | 0 | 3,666 $8,871 | 1 |
Sep 16, 2023
Added 42.1%
|
|
David Roth
Chief Medical Officer |
36,208 | 69,460 | 0 $0 | 12 |
Apr 03, 2024
Reduced 100.0%
|